HMOs in breast milk are the main factor that induces the growth of large numbers of bifidobacteria in the intestine. These bacteria in the gut of breastfed infants use HMO components as an important factor for their growth. CD BioGlyco provides integrated Technologies for HMO Production. Our advanced technology platforms and high-quality services will fully meet your needs.
The milk glycobiota has a major impact on the infant's gut microbiota, which plays a pivotal role in infant health and development. The backbones of human milk oligosaccharides (HMOs) and N-glycans can be modified with fucose and sialic acid to form various recognition motifs. Fucosylated HMOs and N-glycans on milk proteins favor the development of healthy gut microbiota, and the level of fucosylation of these glycans is influenced by the maternal fucosyltransferase 2 gene. This gene expresses the ABO blood type in various secreted body fluids.
LNnDFH II is a neutral HMO. The chemical structure is shown in Fig.1.
Fig.1 Chemical structure of LNnDFH II. (CD BioGlyco)
Enzymatic synthesis of HMOs requires a powerful fucosyltransferase. CD BioGlyco offers high-quality LNnDFH II production services using the principle of enzymatic synthesis.
Helicobacter pylori A 1-3-fucosyltransferase (Hp3FT) truncated at the C-terminal 66 amino acid is a good candidate gene. In the reaction catalyzed by Hp3FT, the receptor substrates are N-acetyllactam (LacNAc) and lactose, with LacNAc being its preferred receptor. LNnDFH II is synthesized enzymatically by altering the ratio of donor to the receptor and controlling the reaction sequence catalyzed by multiple glycosyltransferases with a low guanoside 5'-diphosphate-β-L-focus (GDP-Fuc) to acceptor ratio. For the technology of enzymatic synthesis of oligosaccharides, please refer to Production of HMO by Chemoenzymatic Methods.
In addition, CD BioGlyco provides a series of advanced technical means for HMO Profiling. For example, the structure of oligosaccharides is identified by tandem mass spectrometry and proton nuclear magnetic resonance (NMR).
CD BioGlyco has advanced instrumentation platforms and expertise in glycoscience. In addition, our professional research teams allow us to provide comprehensive services for LNnDFH II production by enzymatic synthesis. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
